14 Months After U.S. FDA Charged India's Lupin, Manufacturing Facility At Mandideep Cleared
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - A long trail of hair splitting audits and investigations came to an end for India's drug maker Lupin as U.S. FDA issued an "All Clear" statement for the company's Mandideep manufacturing site in the central Indian state of Madhya Pradesh